Hoskins P.J., McMurtrie E., Swenerton K.D.
The Vancouver Clinic of the British Columbia Cancer Agency, (formerly A. Maxwell Evans Clinic of the Cancer Control Agency of British Columbia), Vancouver, Canada V5Z 4E6.
Int J Gynecol Cancer. 1992 Jan;2(1):35-40. doi: 10.1046/j.1525-1438.1992.02010035.x.
Etoposide (VP16) was administered intravenously at a dose of 150 mg/m2 daily for 2 days every 2 weeks to 24 patients with progressing epithelial ovarian carcinoma which was resistant to platinum analogues. Using standard response criteria there were five clinical partial responses (21%, 95% confidence limits 5-37%) and three disease stabilizations. However, the aim of our study was to determine if etoposide was non-cross-resistant with platinum analogues and therefore we also developed additional response criteria based on serial CA 125 levels. This was to enable us to differentiate within the heterogeneous group of responses that form the stable disease category. Nine of 23 patients (39%, 95% confidence limits 19-59%) demonstrated a fall (all rising prior to etoposide) and of these, three had a serologic partial remission (65% or greater fall). The serologic and clinical responses were strongly correlated. Falling CA 125 levels occurred in the eight patients with either clinical partial responses or disease stabilizations.
依托泊苷（VP16）以150mg/m²的剂量静脉给药，每2周每日给药1次，共2天，治疗24例对铂类类似物耐药的进展期上皮性卵巢癌患者。按照标准疗效标准，有5例临床部分缓解（21%，95%置信区间5%-37%）和3例病情稳定。然而，我们研究的目的是确定依托泊苷与铂类类似物是否无交叉耐药性，因此我们还根据连续的CA 125水平制定了额外的疗效标准。这使我们能够在构成病情稳定类别的异质性反应组中进行区分。23例患者中有9例（39%，95%置信区间19%-59%）CA 125水平下降（均在依托泊苷治疗前升高），其中3例有血清学部分缓解（下降65%或更多）。血清学反应和临床反应密切相关。8例有临床部分缓解或病情稳定的患者CA 125水平下降。
